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Abstract
Nontuberculous mycobacteria include 198 mycobacterial species. Among these,Mycobacteroides abscessus is a rapidly growing
mycobacteria that causes lung and skin infections. M. abscessus lung infections are difficult to treat due to the high levels of
resistance to several classes of antibiotics. The current treatment is based on combining at least two or three antibiotics. However,
treatment outcomes remain very poor. The objective was to compare the in vitro activity of amikacin, tigecycline, imipenem, and
clarithromycin, alone and in two different three-drug combinations (amikacin/tigecycline/imipenem and amikacin/tigecycline/
clarithromycin) against seven M. abscessus subsp. abscessus clinical isolates using the time-kill assay. The two combinations
showed greater activity than the antibiotics tested individually. Even though both combinations showed similar activity as well as
no antagonistic activity, the combination including imipenem could not be an alternative treatment against M. abscessus subsp.
abscessus lung infections caused by clarithromycin susceptible isolates. However, this combination could be considered against
clarithromycin resistant isolates. Future studies are necessary to confirm this hypothesis.
Introduction
The nontuberculous mycobacteria (NTM) family includes
198 species, the majority of which do not cause disease in
humans [1]. NTM are naturally found in the environment,
from soil to water systems [2]. Recently, mycobacterial
species have been divided into five new genera: Myco-
bacterium, Mycolicibacter, Mycolicibacterium, Mycolici-
bacillus, and Mycobacteroides [3]. Over the last years,
infections caused by NTM have significantly increased [4].
Among these NTM, Mycobacteroides abscessus is a rapidly
growing mycobacteria (RGM) that causes lung and skin
infections which are difficult to treat due to its resistance to
most classes of antibiotics [2, 4]. This RGM is classified
into three subspecies: M. abscessus subsp. abscessus, M.
abscessus subsp. massiliense and M. abscessus subsp.
bolletii [2, 3, 5]. The identification to subspecies level is
important since their resistance profiles to macrolides are
different. Macrolides, and specifically clarithromycin are
among the most active antibiotics against M. abscessus. The
resistance to macrolides can be either constitutive (rrl gene)
or inducible (erm41 gene). The most frequent is the indu-
cible resistance, due to the presence of a functional erm41
gene that codes for a methylase. Accordingly, M. abscessus
subsp. massiliense is usually susceptible to macrolides since
the erm41 gene is truncated and not functional. M.
abscessus subsp. bolletii is innately resistant to macrolides.
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Most of M. abscessus subsp. abscessus also exhibit indu-
cible macrolide resistance, but some isolates remain sus-
ceptible due to a non-functional erm41 gene. Although
there are geographical differences, the most commonly
isolated is M. abscessus subsp. abscessus [4, 6].
M. abscessus lung infections are particularly common in
patients with underlying respiratory conditions, such as
cystic fibrosis and bronchiectasis [5]. These infections
require treatment, but management is difficult due to high
levels of natural and acquired resistance to frequently used
antibiotics. Moreover, the presence of mucus and other
secretions at the site of infection makes the entry of anti-
biotics difficult. Depending on the macrolide resistance
profile, the current guidelines of the British Thoracic
Society recommend the administration of different intrave-
nous (IV) and oral antibiotics (e.g., IV amikacin, IV tige-
cycline, IV imipenem, and oral clarithromycin) for 1 month
during the initial phase followed by oral and inhaled anti-
biotics (e.g., oral clofazimine, oral moxifloxacin and neb-
ulized amikacin) for a minimum of 12 months during the
continuation phase. The use of macrolides is recommended
even in the presence of inducible resistance, but not when
constitutive resistance associated to the rrl gene is found
[6, 7]. On the other side and despite its IV administration,
tigecycline has better activity than former drugs used in
combination with amikacin, such as doxycycline, tetra-
cycline and minocycline [8]. Nevertheless, side effects are
common and treatment outcomes are very often poor [2].
Hence, it is of great importance to develop new antibiotics
and antibiotic combinations.
The treatment regimens available for M. abscessus lung
infections consist of the administration of different anti-
biotics in combination. Therefore, it is necessary to deter-
mine the efficacy of these combinations as well as of that of
the antibiotics alone. The time-kill assay establishes the
in vitro pharmacodynamics of antibiotics by detecting the
rate at which an antibiotic concentration kills bacteria
along time [9].The main goal was to compare the in vitro
activity of four different antibiotics, amikacin, tigecycline,
imipenem, and clarithromycin alone and in two different
three-drug combinations (amikacin/tigecycline/imipenem
and amikacin/tigecycline/clarithromycin) against M.
abscessus subsp abscessus clinical isolates using the in vitro
time-kill assay.
Material and methods
Mycobacteroides abscessus subsp. abscessus clinical
isolates
Seven clinical isolates of M. abscessus subsp. abscessus
were selected from a strain collection of the Microbiology
Department of the Hospital Clinic of Barcelona
(Spain). They were previously identified at subspecies
level using GenoType® NTM-DR (Hain Lifescience
GmbH, Nehren, Germany). In addition, Sensititre™ AST
RAPMYCO plates (Thermo Fisher Scientific, MA, USA)
were used in accordance to manufacturers recommenda-
tions for antibiotic susceptibility testing, incubating
the plates for 3 days, except for clarithromycin whose
incubation was prolonged for up to 7 and 14 days to detect
the presence of inducible resistance. The seven
isolates selected had the following range of minimum
inhibitory concentrations (MICs) to the antibiotics tested:
4–16 µg ml−1 for amikacin, 0.125–0.5 µg ml−1 for tige-
cycline, 8–64 µg ml−1 for imipenem, and 0.5–4 µg ml−1
for clarithromycin (Table 1). Stocks of each isolate were
preserved at −80 °C in skim milk and were thawed for
each assay.
Antibiotics
The four antibiotics tested were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Amikacin and imipenem
were dissolved in sterile distilled water. Clarithromycin was
dissolved in dimethyl sulfoxide (DMSO) (0.002% final
concentration) and sterile distilled water. All the antibiotics
were sterilized by filtration and stored at −20 °C.
Tigecycline preparation
Tigecycline was prepared as described by Jitkova et al. [10]
due to its poor stability. It was dissolved in DMSO (1mgml−1)
and saline solution containing ascorbic acid (3mgml−1)
(Sigma-Aldrich) and pyruvate (60mgml−1) (Sigma-Aldrich)
and adjusted to pH 7.0. With this formulation, tigecycline
remained stable for up to 7 days when protected from
light [10].
Table 1 Minimum inhibitory concentrations (MICs) of the M.
abscessus clinical isolates studied
Isolate MICs (µg ml−1)
AMK TGC IPM CLR
M. abscessus 1 8 0.125 64 0.5
M. abscessus 2 8 0.5 16 4
M. abscessus 3 16 0.25 8 1
M. abscessus 4 16 0.25 64 0.5
M. abscessus 5 8 0.25 8 2
M. abscessus 6 8 0.25 32 0.5
M. abscessus 7 4 0.5 8 0.5
M. abscessus MIC90 16 0.5 64 4
AMK amikacin, TGC tigecycline, IPM imipenem, CLR clarithromycin
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Inoculum preparation
All of the isolates were grown in BDTM Columbia Agar
with 5% Sheep Blood plates (Becton Dickinson, Sparks,
MD). Then, they were subcultured in Middlebrook 7H9
liquid medium (Becton Dickinson) supplemented with 10%
oleic acid-albumin-dextrose-catalase (Comercial Bellés,
Tarragona, Spain) and 0.25% Tween 80 (Merck, Darmstadt,
Germany) to avoid bacilli clump formation. Finally, the M.
abscessus subsp abscessus cultures were homogenized by
agitation and adjusted to the desired concentration using a
nephelometer (CrystalSpec™; Becton Dickinson).
Minimum inhibitory concentrations
The MICs of each antibiotic were determined in 96-well
plates (Smartech Biosciences, Barcelona, Spain). Briefly,
100 µl of Mueller Hinton broth were added to each well.
Then, serial dilutions of the antibiotics ranging from 512 to
0.25 µgml−1 were made. Finally, 100 µl of inoculum at a
concentration of 0.5 McFarland (5 × 106 CFUml−1) were
added. Positive control wells consisted of 100 µl of Mueller
Hinton and 100 µl of inoculum (5 × 106 CFUml−1). Negative
control wells were prepared by adding 200 µl of Mueller
Hinton. Plates were incubated at 30 °C for 3 days and for up
to 14 days in the case of clarithromycin. After incubation,
visual reading was performed. The MIC was interpreted as the
lowest antibiotic concentration preventing growth. All the
experiments were performed in duplicate.
Time-kill assays
A previously described protocol was adapted for the
present study [11]. Briefly, the time-kill assays were
performed by dispensing 600 µl of the corresponding
antibiotic concentration (amikacin, tigecycline, imipenem,
or clarithromycin) and 500 µl of inoculum (final con-
centration of 5 × 105 CFU ml−1) into tubes with 7.8 ml of
Mueller Hinton broth. For the three-drug combinations
(amikacin/tigecycline/imipenem and amikacin/tigecy-
cline/clarithromycin), 200 µl of each of the three anti-
biotics were dispensed into the tubes. Amikacin and
imipenem were tested at 2× MIC and tigecycline and
clarithromycin at 4× MIC. Control growth tubes con-
taining 500 µl of sterile distilled water instead of antibiotic
were also included. All of the tubes were incubated at
37 °C in a 5% CO2 atmosphere for 6 days. Time points
were established at days 0, 1, 3, and 6. At the defined time
points, a volume of 500 µl was removed from each liquid
culture. The number of viable mycobacteria in each cul-
ture was determined by plating 10-fold serial dilutions on
Middlebrook 7H11 medium (Becton Dickinson). The
7H11 agar plates were incubated at 37 °C in a 5% CO2
atmosphere for 3 days, after which colony-forming units
were counted. All the experiments were performed in
duplicate.
Data analysis of the time-kill assays
The means of the log10 CFUml
−1 values were plotted
against time for each isolate. The results were interpreted by
the effect of the combinations compared with the most
active antibiotic tested individually. Synergy was con-
sidered when the activity of the combinations was 2 log10
higher than the most active antibiotic alone. Antagonism
was determined when the activity of the combinations was
2 log10 lower compared to the most active antibiotic alone.
Finally, a difference of less than 2 log10 lower or higher was
considered indifferent.
Statistical analysis
Significant differences between the two combinations
(amikacin/tigecycline/imipenem or amikacin/tigecycline/
clarithromycin) were analyzed using the Wilcoxon
Mann–Whitney test. Results showing P ≤ 0.05 were con-
sidered as statistically significant. Calculations were per-
formed using STATA 13.0 software (Stata Corporation,
College Station, TX, USA).
Results
Four different antibiotics, amikacin, tigecycline, imipe-
nem, and clarithromycin, alone and in combination
(amikacin/tigecycline/imipenem and amikacin/tigecy-
cline/clarithromycin) were tested against clinical isolates
of M. abscessus subsp. abscessus using the time-kill
assay. The results observed during the 6-day period are
summarized in Table 2.
In the present study at day 6, amikacin and tigecycline
showed a mean 2.01 and 0.46 log10 CFU ml
−1 decrease,
respectively, compared with the initial inoculum (5.70 log10
CFUml−1). Imipenem and clarithromycin displayed a mean
1.48 and 1.27 log10 CFUml
−1 decrease, respectively. The
combination of amikacin/tigecycline/imipenem showed a
mean decrease of 2.58 log10 CFUml
−1. Finally, the com-
bination of amikacin/tigecycline/clarithromycin displayed a
mean decrease of 3.02 log10 CFUml
−1. Although being less
pronounced, these decreases were also observed at day 3.
No significant differences were observed among the two
replicates of each isolate. The most active individual anti-
biotic was amikacin followed by imipenem and clari-
thromycin. Both combinations were indifferent (neither
synergistic nor antagonistic) showing more activity than the
antibiotics tested individually. Moreover, no significant
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differences (P ≥ 0.05) were observed between the activities
of the two three-drug combinations.
Discussion
In this study, the effects of amikacin, tigecycline, imipenem,
and clarithromycin individually and in two three-drug
combinations were investigated as these antibiotics are
usually administered during the treatment of lung infections
caused by M. abscessus. To our knowledge, there are few
studies on the effect of these antibiotics againstM. abscessus
clinical isolates using the time-kill assay [12, 13]. This
method is adequate for studying the activity of antibiotics
and determining their pharmacodynamics [14]. Furthermore,
the time-kill assay has been largely used in clinical micro-
biology laboratories and has demonstrated to be reliable and
consistent in the study of different microorganisms, includ-
ing NTM [11, 15–18]. The antibiotic susceptibility testing
forM. abscessus is read at day 3 in microbiological practice.
However, in this study the time points were established at
days 3 and 6 in order to study the accumulated activity of the
antibiotics alone and of the three-drug combinations.
Regarding the antibiotics, it is well-known that tigecycline
has poor stability. In this study, it was prepared as described
by Jitkova et al. and remained stable for up to 7 days [10].
This novel formulation allows the testing of tigecycline, a
drug frequently used in the treatment of M. abscessus lung
infections given that it is more effective than doxycycline
and other tetracyclines [8]. Concerning imipenem, it shows
poor stability in formulations parenterally administered to
patients. This poor stability has been attributed to changes in
pH and in the concentrations of sodium bisulfite and L-
cysteine [19]. Nonetheless, our in vitro results showed
activity of all the antibiotics and antibiotic combinations at
both days 3 and 6.
Currently, the majority of patients with lung infections
by M. abscessus receive more than two antibiotics in
combination during the course of treatment. However, there
is no standard combination and most of the treatments are
based on empirical experience. In addition, most studies
only investigate the activity of antibiotics in two-drug
combinations. Some of them include few of the antibiotics
analyzed in the present study, but none includes three-drug
combinations [12, 15, 16].
In this study we used isolates of M. abscessus subsp.
abscessus, the most isolated subspecies in our area. From
a strain collection we selected seven clinical isolates
susceptible to macrolides, with the aim to compare the
two three-drug combinations. The results show that both
combinations had good activity and did not show statis-
tically significant differences, although the reduction in
log10 CFU ml
−1 with the combination including imipenem
was lower than of that including clarithromycin. For this
reason and due to the IV administration of imipenem, the
combination of amikacin/tigecycline/imipenem could not
be recommended as an alternative in the treatment of M.
abscessus subsp. abscessus lung infections caused by
clarithromycin susceptible isolates. However, in the light
of the results obtained, this combination could be con-
sidered against clarithromycin resistant isolates. Future
studies are required to confirm this hypothesis. This is
especially important, since at least 14 months of treatment
are necessary and outcomes remain very poor, with suc-
cess rates of only 30–50% [20].
Furthermore, systems of antibiotic administration that
have already proven to be effective against NTM lung
infections, such as inhaled liposomal antibiotics and other
nanoparticle-based antibiotic delivery systems, should be
further developed. These forms of administration are cur-
rently used for amikacin [21]. In addition, imipenem phy-
sicochemical properties also allow its administration using
these new delivery systems [22].
In conclusion, both three-drug combinations, amikacin/
tigecycline/imipenem, and amikacin/tigecycline/clari-
thromycin, showed similar in vitro activity against M.
abscessus subsp. abscessus clinical isolates as well as no
antagonistic activity. The combination including imipenem
is not a reliable alternative against M. abscessus subsp.
abscessus lung infections caused by isolates susceptible to
clarithromycin. However, this combination should be fur-
ther studied against clarithromycin resistant isolates.
Table 2 Mean colony-forming values (log10 CFUml
−1) and reduction in growth compared with the initial inoculum (Δ) at the defined time points
of the time-kill assay






ΔDay 1 Day 3
(log10 CFUml
−1)




GC 6.85 ± 0.09 7.35 ± 0.42 0.5 8.18 ± 0.39 1.33 8.80 ± 0.65 1.95
AMK 6.85 ± 0.10 6.37 ± 0.38 −0.48 5.62 ± 0.49 −1.23 4.84 ± 0.92 −2.01
TGC 6.85 ± 0.11 6.73 ± 0.43 −0.12 6.50 ± 0.33 −0.35 6.39 ± 0.31 −0.46
IPM 6.85 ± 0.12 6.12 ± 0.64 −0.73 5.47 ± 0.94 −1.38 5.37 ± 0.35 −1.48
CLR 6.85 ± 0.13 6.58 ± 0.42 −0.27 6.02 ± 0.40 −0.83 5.58 ± 0.60 −1.27
AMK/TGC/IPM 6.85 ± 0.14 6.10 ± 0.75 −0.75 5.42 ± 0.60 −1.43 4.27 ± 0.67 −2.58
AMK/TGC/CLR 6.85 ± 0.15 6.20 ± 0.49 −0.65 5.46 ± 0.70 −1.39 3.83 ± 0.90 −3.02
CFU colony-forming unit, GC growth control, AMK amikacin, TGC tigecycline, IPM imipenem, CLR clarithromycin
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